The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.5975
Bid: 0.57
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.13 (22.807%)
Open: 0.5975
High: 0.00
Low: 0.00
Prev. Close: 0.5975
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fruitflow powder has GRAS status affirmed in US

30 Apr 2013 07:00

RNS Number : 5282D
Provexis PLC
30 April 2013
 



30 April 2013

Provexis plc

 

Fruitflow® powder has GRAS status affirmed in the United States

 

Provexis plc ("Provexis" or the "Company"), a business that develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, announces that an independent Expert Panel in the United States has affirmed the powder version of the company's Fruitflow® heart-health ingredient to be Generally Recognised as Safe ('GRAS'), paving the way for the powder version of Fruitflow® to be marketed in the United States.

 

The powder version of Fruitflow® has been scaled up and commercialised by the company's Alliance partner DSM Nutritional Products ("DSM") and first orders have been received from six customers in international markets. The powder version is suitable for a range of dietary supplement products including soft gels, capsules and tablets, and it will enable manufacturers to target a broader consumer base. DSM has launched the powder version of Fruitflow® internally to its global sales force, and the product will be launched commercially by DSM at the Vitafoods exhibition in Geneva on 14 May.

 

Stephen Moon, CEO of Provexis, commented:

"GRAS affirmation of the powder version of Fruitflow is a significant development for the product which will help to unlock the substantial commercial opportunities available in North America. Our Alliance with DSM has made very good progress in commencing the commercialisation of Fruitflow, and GRAS affirmation of Fruitflow powder will help to drive the continuing good levels of customer interest from a range of customers across the globe."

 

ends-

 

For further information please contact:

 

Provexis plc

Stephen Moon, Chief Executive Tel: 01753 861777

 

Cenkos Securities plc

Max Hartley / Bobbie Hilliam Tel: 020 7397 8900

 

Haggie Financial LLP

Matthew Longbottom / Peter Rigby Tel: 020 7417 8989

matthew.longbottom@haggie.co.uk

 

 

Notes to Editors

 

About Fruitflow®

Fruitflow®, a water-soluble tomato concentrate developed by Provexis, is a breakthrough in anti-thrombotic food technology. In human trials, consumption of Fruitflow® has been proven to reduce platelet aggregation in 97% of subjects. The effect takes place within three hours of consumption and lasts for up to eighteen hours, making it ideal for daily dosage in functional foods or dietary supplements. The syrup version of Fruitflow® can be used as an ingredient in food and beverages, and the powder version is suitable for a range of dietary supplement products including soft gels, capsules and tablets.

 

The syrup and powder versions of Fruitflow® are GRAS (Generally Regarded as Safe) in the US and are not regarded as Novel Foods in the EU, clearing them for wide use in foods, beverages and supplements. In May 2009, the Fruitflow® technology was the first to be substantiated by the European Food Safety Authority ("EFSA") under the new Article 13(5) for proprietary and emerging science. In December 2009 the European Commission authorised the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow", which was the first wording to be authorised under Article 13(5).

 

The technology has been granted patents in the EU, US, Australia, Canada and Mexico, with Japan pending. Further patents have been filed for the bioactive components of Fruitflow® and for other developmental areas such as deep vein thrombosis and triglyceride lowering.

 

About Royal DSM N.V.

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of about €9.1 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

 

About DSM Nutritional Products

DSM Nutritional Products, a wholly-owned business unit of Royal DSM N.V., is one of the world's leading suppliers of vitamins, carotenoids and other ingredients to the feed, food, pharmaceutical and personal care industries. The business has sales of more than €3 billion and a long tradition of innovation that benefits people, planet and profit. DSM Nutritional Products is a fully integrated global operation, organised into three market-facing businesses: Animal nutrition & health, Human nutrition & health and Personal care.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKLNASFDEFF
Date   Source Headline
27th Oct 20094:35 pmRNSPrice Monitoring Extension
20th Oct 20097:00 amRNSChange of Adviser
15th Oct 200910:46 amRNSResult of General Meeting
12th Oct 20097:00 amRNSProvexis Announces Update on Human Trial
7th Oct 20094:36 pmRNSHolding(s) in Company
2nd Oct 20091:09 pmRNSHolding(s) in Company
29th Sep 200910:00 amRNSPosting of Circular
28th Sep 20092:40 pmRNSHolding(s) in Company
25th Sep 20097:00 amRNSSubscription and Notice of General Meeting
23rd Sep 20099:54 amRNSShare Price Movement
17th Sep 20092:15 pmRNSDirectorate Change
10th Sep 20093:10 pmRNSResult of AGM
8th Sep 200912:33 pmRNSAdditional Listing
3rd Sep 20094:12 pmRNSAdditional Listing
3rd Sep 200912:37 pmRNSHolding(s) in Company
28th Aug 20098:53 amRNSRecent share price increase
26th Aug 20093:08 pmRNSDisposal of Provexis Holding
25th Aug 200910:32 amRNSHolding(s) in Company
25th Aug 200910:27 amRNSHolding(s) in Company
17th Aug 20099:25 amRNSAnnual Financial Report
11th Aug 20094:22 pmRNSHolding(s) in Company
11th Aug 20097:00 amRNSCommencement of Clinical Trial
10th Aug 20099:43 amRNSRecent share price movement
2nd Jul 20094:44 pmRNSHolding(s) in Company
9th Jun 20097:00 amRNSAudited Results Year ended 31 March 2009
28th May 20097:00 amRNSEuropean Health Claim Adoption for Fruitflow
4th Feb 20097:00 amRNSSirco Launch
3rd Feb 200912:39 pmRNSR&D Pipeline Update
3rd Feb 200911:32 amRNSFurther re Agreement
2nd Dec 20087:00 amRNSInterim Results
3rd Oct 200810:47 amRNSHolding(s) in Company
2nd Oct 20083:17 pmRNSDirector/PDMR Shareholding
2nd Oct 200811:08 amRNSResult of AGM
1st Oct 20087:00 amRNSDirectorate Change
16th Sep 20083:22 pmRNSAdditional Listing
11th Sep 20089:49 amRNSAnnual Report and Accounts
2nd Sep 200811:44 amRNSHolding(s) in Company
1st Sep 20085:50 pmRNSGrant of options
1st Sep 200812:57 pmRNSDirectorate Change
29th Aug 20089:32 amRNSHolding(s) in Company
26th Aug 200810:41 amRNSResult of Meeting
21st Aug 20087:00 amRNSJoint Venture Project
4th Aug 20087:00 amRNSProvexis Fundraising
1st Aug 20084:32 pmRNSFinal Results
1st Aug 20084:30 pmRNSPlacing and Share Reorganisat
9th Jun 20084:52 pmRNSResponse to Share Price Movem
27th Mar 200810:07 amRNSHolding(s) in Company
20th Mar 20083:08 pmRNSHolding(s) in Company
3rd Mar 20089:51 amRNSHolding(s) in Company
25th Jan 200810:39 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.